Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Free fatty acid receptor 2 (FFAR2, GPR43) and Free fatty acid receptor 3 (FFAR3, GPR41) are the primary G protein-coupled receptors for short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate. These receptors are expressed on the surface of multiple cell types—including immune cells, gut epithelial cells, and neurons—and play key roles in regulating host metabolism, energy homeostasis, hormone and neurotransmitter secretion, and immune responses. They serve as molecular mediators of gut microbiota-derived SCFA effects on both local intestinal and systemic physiology. Dysregulation or impaired signaling through these receptors has been linked to inflammatory diseases, cardiovascular disease, and neurodegenerative conditions. While termed 'SCFA receptors', this grouping encompasses several GPCRs; the most functionally and therapeutically relevant are FFAR2 and FFAR3.
FFA2 and FFA3 are activated by binding SCFAs, leading to G protein-mediated intracellular signaling that impacts inflammation, metabolism, and hormone secretion. Activation of FFA2/FFA3 results in modulation of cyclic AMP, calcium signaling, and downstream cytokine release.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SCFA receptors.